Management of recurrent disease;Medikamentöse rezidivtherapie

Gynakologe

Volumn 34, Issue 11, 2001, Pages 1020-1023

  Wagner, U ^a   Blohmer, J U ^b   Luck H J ^c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Ovarian cancer; Platinum resistant; Platinum sensitive; Recurrent disease

Indexed keywords

ALTRETAMINE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PACLITAXEL; TOPOTECAN; TREOSULFAN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; HUMAN; MEDICAL DECISION MAKING; OVARY CANCER; QUALITY OF LIFE; RECURRENT CANCER; TREATMENT FAILURE;

EID: 0035160398     PISSN: 00175994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001290101110     Document Type: Article

References (7)

1. Advanced Epithelial Ovarian Cancer: 1998 Consensus Statements
2. 2nd-line chemotherapie nach platin- oder platin-paclitaxel-haltiger primär-therapie beim ovarialkarzinom: Eine systematische übersicht der publizierten daten bis 1998
3. Responses to salvage therapy in ovarian cancer: A critical need for precise definnitions of the treated population
4. Cyclophosphamide and cisplatin compared with paditaxel and cisplatin in patients with stage III and IV ovarian cancer
5. Maligne ovarialtumoren
6. Carcinoma of the ovary
7. Second-line therapy for ovarian cancen